GSK sees commercial opportunity in antimicrobial resistance

Long after most pharmas moved on from the commercially challenging antimicrobial resistance field, GSK is reaffirming its commitment to novel antibiotics and infectious diseases more broadly, and believes it’s found a commercial path forward for at least one new oral antibiotic.

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) announced on Tuesday that a pair of Phase III trials evaluating gepotidacin in female patients with uncomplicated urinary tract infection (uUTI) were stopped early for efficacy following a pre-planned interim analysis by an Independent Data Monitoring Committee. ...